Централна медицинска библиотека neurology and psychiatry редакционна колегия

На табл. 2 са представени разходите за лечение на умерена до тежка депресия с доза от 20 mg Escitapolram при цени на 10 mg таблетки. За дозовите форми от 10mg стойността на лечението е изчислена за 2 опаковки, а за дозовите форми от 20 mg за една опаковка. Годишните разходи за лечение варират между 216 и 720 лв.

Таблица 2. Разходи за лечение на умерена до тежка депресия с 20 mg Escitapolram

	CIP (без ДДС)	Дозировка	Количество за един терапевтичен курс	Разходи за 1 месец (без ДДС)	Разходи за 6 месеца (без ДДС)	Разходи за 12 месеца (без ДДС)
Cipralex	29,98	20 mg/ден	2 опак.	59,96	359,76	719,52
Lenuxin	19,56	20 mg/ден	2 опак.	39,12	234,72	469,44
Escitalopram	18,42	20 mg/ден	2 опак.	36,84	221,04	442,08
Escitalon	14,69	20 mg/ден	2 опак.	29,38	176,28	352,56
Escitil	13,69	20 mg/ден	2 опак.	27,38	164,28	328,56
Esoprex	13,63	20 mg/ден	2 опак.	27,26	163,56	327,12
Escitasan	9,94	20 mg/ден	2 опак.	19,88	119,28	238,56
Eloryqa	9,94	20 mg/ден	2 опак.	19,88	119,28	238,56
Escipram	11,54	20 mg/ден	2 опак.	23,08	138,48	276,96
Alvocital	17,88	20 mg/ден	2 опак.	35,76	214,56	429,12
Essobel	18,01	20 mg/ден	1 опак.	18,01	108,06	216,12

Оценка на бюджетното въздействие

При лечение на лека депресия с доза 10 mg дневно, годишните разходи с Еssobel са най-ниски в сравнение с всички останали продукти с INN Escitalopram. Essobel е алтернативата с най-ниски разходи, следван от Еscitan и Eloryqa. Тези алтернативи спестяват разходи на НЗОК и намаляват референтната реимбурсна стойност на дефинираната дневна доза (ДДД) (фиг. 1).

При лечение на умерено тежка депресия с доза 20 mg дневно годишните разходи също са най-ниски с Essobel, тъй като това е единственият лекарствен продукт с дозова концентрация от 20 mg (фиг. 2).


Фиг. 1. Бюджетно въздействие при дозов режим от 10 mg дневно


Фиг. 2. Бюджетно въздействие при дозов режим от 20 mg дневно

Заключение

Нашето проучване потвърждава други изследвания, че развитието на генеричен лекарствен пазар води до съществено намаляване на цените на лекарствените продукти [48]. Практиката у нас показва, че по-големият брой генерични алтернативи от едно INN довежда до трайно и систематично намаление на цените, което спестява бюджетни средства.

Световните проучвания също така показват, че разходите за лечение на депресията с генеричен Escitalopram са сред най-ниските спрямо останалите INN и употребата му ще доведе до спестяване на средства от здравните фондове.

Библиография

1. 
   Wells, K. B. et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. – J. Am. Med. Assoc., 262, 1989, 914-919.
   
2. 
   Murray, C. J. L., A. D. Lopez. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass., Harvard University Press, 1996.
   
3. 
   Thase, M. E. Long-term nature of depression. – J. Clin. Psychiatry, 60, 1999, (Suppl. 14), 3-9.
   
4. 
   Croom, K. et G. L. Plosker. Escitalopram: a pharmacoeconomic review of its use in depression. – Pharmacoeconomics, 21, 2003, № 16, 1185-1209.
   
5. 
   Sullivan, P. W. et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. – CNS Drugs, 18, 2004, № 13, 911-932.
   
6. 
   Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatment (CANMAT). Clinical guidelines for the treatment of depressive disorders. – Can. J. Psychiatry, 46, 2001, Suppl. 1, 1S-92S.
   
7. 
   Institute for Clinical Systems Improvement. Health care guideline: major depression in adults in primary care Available from URL: http://www.isci.org
   
8. 
   Bauer, M. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 1. Acute and continuation treatment of major depressive disorder. – World J. Biol. Psychiatry, 3, 2002, 5-43.
   
9. 
   Owens, M. J., D. L. Knight et C. B. Nemeroff. Secondgeneration SSRIs: Human monoamine transporter binding profile of escitalopram and R-fluoxetine. – Biol. Psychiatry, 50, 2001, 345-350.
   
10. 
    Gorman, J., A. Korotzer et G. Su. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. – CNS Spectrums, 7, 2002, (Suppl. 4), 40-44.
    
11. 
    Lepola, U. M., H. Loft et E. H. Reines. Escitalopram (10 to 20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. – Int. Clin. Psychopharmacol., 18, 2003, 211-217.
    
12. 
    Auquier, P. et al. Comparison of escitalopram and citalopram efficacy: a meta-analysis. – Int. J. Psychiatry Clin. Prac., 7, 2003, 259-268.
    
13. 
    WHO initiative on depression in public health, http://www.who.int/mental_health/­management/­depression/definition/en/. Аssessed on 29.08.2012.
    
14. 
    David, S. et al. Escitalopram and paroxetine in the treatment of generalised anxiety disorder. – Br. J. Psychiatry, 9, 2006, 189, 264 -272.
    
15. 
    Lepola, U.M. et al. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. – Int. Clin. Psychophar­macol., 18, 2003, № 4, 211-217.
    
16. 
    Bose, A., D. Li et C. Gandhi. Escitalopram in the acute treatment of depressed patients aged 60 years or older. – Am. J. Geriat. Psychiat., 16, 2008, 14-20.
    
17. 
    Burke, W. J. et al. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. – J. Clin. Psychiatry, 63, 2002, 331-336.
    
18. 
    Kasper, S., H. de Swart et F. H. Andersen. Escitalopram in the treatment of depressed elderly patients. – Am. J. Geriat. Psychiat., 13, 2005, 884-891.
    
19. 
    Nierenberg, A. A. et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. – Curr. Med. Res. Opin., 23, 2007, 401-416.
    
20. 
    Rapaport, M. H., A. Bose et H. Zheng. Escitalopram continuation treatment prevents relapse of depressive episodes. – J. Clin. Psychiat., 65, 2004, 44-49.
    
21. 
    Wade, A. et H. F. Andersen. The onset of effect for escitalopram and its relevance for the clinical management of depression. – Curr. Med. Res. Opin., 22, 2006, 2101-2110.
    
22. 
    Llorca, P. M. et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. – Int. J. Clin. Prac., 59, 2005, 268-275.
    
23. 
    Lepola, U., A. Wade et H. F. Andersen. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. – Int. Clin. Psychopharm., 19, 2004, 149-155.
    
24. 
    Gorman, J. M., A. Korotzer et G. Su. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. – CNS Spectrums, 7, 2002, 40-44.
    
25. 
    Yevtushenko, V. Y. et al. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. – Clin. Ther., 29, 2007, 2319-2332.
    
26. 
    Burke, W. J. et al. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. – J. Clin. Psychiat., 63, 2002, 331-336.
    
27. 
    Colonna, L., H. F. Andersen et E. H. Reines. A randomized, doubleblind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. – Curr. Med. Res. Opin., 21, 2005, 1659-1668.
    
28. 
    Moore, N., H. Verdoux et B. Fantino. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. – Int. Clin. Psychopharm., 20, 2005, 131-137.
    
29. 
    Kasper, S. et al. Onset of action of escitalopram compared with other anti­de­pressants: results of a pooled analysis. – Int. Clin. Psychopharm., 21, 2006, 105-110.
    
30. 
    Kennedy, S. H., H. F. Andersen et M. E. Thase. Escitalopram in the treatment of major depressive disorder: a meta-analysis. – Curr. Med. Res. Opin., 25, 2009, 161-175.
    
31. 
    Boulenger, J. P. et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. – Curr. Med. Res. Opin., 22, 2006, 1331-1341.
    
32. 
    Baldwin, D. S. et al. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. – Int. Clin. Psychopharm., 21, 2006, 159-169.
    
33. 
    Mao, P. X. et al. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. – Depress. Anxiety, 25, 2008, № 1, 46-54.
    
34. 
    Kasper, S. et al. Superiority of escitalopram to paroxetine in the treatment of depression. – Eur. Neuropsychopharm., 19, 2009, 229-237.
    
35. 
    Bielski, R. J., D. Ventura et C. C. Chang. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. – J. Clin. Psychiatry, 65, 2004, № 9, 1190-1196.
    
36. 
    Montgomery, S. A., A. K. Huusom et J. Bothmer. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. – Neuropsychobiology, 50, 2004, 57-64.
    
37. 
    Ventura, D. et al. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. – Curr. Med. Res. Opin., 23, 2007, № 2, 245-250.
    
38. 
    Clayton, A. H. et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. – J. Clin. Psychiatry, 67, 2006, № 5, 736-746 .
    
39. 
    Nierenberg, A. A. et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. – Curr. Med. Res. Opin., 23, 2007, № 2, 401-416.
    
40. 
    Baldwin, D. S., E. H. Reines et E. Weiller. Escitalopram therapy for major depression and anxiety disorders. – Ann. Pharmacother., 41, 2007, 1583-1592.
    
41. 
    Koen, M. et al. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in belgium. – Clin. Ther., 27, 2005, 111-124.
    
42. 
    Nordström, G. et al. Cost-Effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder. – Value Health., 15, 2012, № 2, 231-239.
    
43. 
    Sullivan, P. W. et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. – CNS Drugs, 18, 2004, 911-932.
    
44. 
    Wade, A. G. et al. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. – Curr. Med. Res. Opinion, 21, 2005, № 4, Health & Medical Compl. 631-641.
    
45. 
    Wade, A. G. et al. Pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. – Clin. Ther., 27, 2005, № 4, 486-496.
    
46. 
    Nuijten, M. J. et al. Cost-effectiveness of escitalopram in major depressive disorder in the Dutch health care setting. – Clin. Ther., 34, 2012, № 6, 1364-1378.
    
47. 
    Ramsberg, J., C. Asseburg et M. Henriksson. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. – PLoS One, 7, 2012, № 8, e42003.
    
48. 
    Manova, M. et al. Impact of generic competition on market share and prices of cardiovascular medicines on the Bulgarian pharmaceutical market. – J. Public Health, 19, 2011, № 1, 91-100.
    

 Адрес за кореспонденция:

М. Манова

Фармацевтичен факултет

Медицински университет

ул. „Дунав” № 2

1000 София

e-mail: manoela_manova@yahoo.com

Каталог: cmb htm
cmb htm -> Е-библиотека външни или вътрешни
cmb htm -> Централна Медицинска Библиотека и фирма Elsevier
cmb htm -> Абонаментен списък – 2016